A lasting sleep reset is a stronger claim than improvement during a brief study. To support it, research would need to follow people after treatment, define durable benefit and separate that benefit from other changes.
Read the follow-up period literally
The 1987 study abstract reported persistence into the first post-treatment observation night. That is a limited observation window. It is not evidence that insomnia was permanently corrected or that benefits persist for months.
The FDA's later assessment also identified important design limitations in the historical research. Those limitations should travel with the positive findings when they are summarized.
A carryover observation can generate a hypothesis about duration. It cannot establish an entire cycle-and-restart strategy.
Persistence needs its own comparison
A convincing durability study would define the treatment period, follow-up interval and outcome in advance. It would track other care, withdrawals and adverse events rather than relying only on people who chose to report a good result.
If a person sleeps better after stopping, the improvement may be genuine while its cause remains uncertain. If sleep worsens again, that does not prove that DSIP must be repeated or that a tolerance break is needed.
These are separate hypotheses requiring evidence, not automatic explanations for whatever happens next.
Frame the clinical goal more usefully
Instead of asking how often to reset sleep, describe the recurring pattern and its daytime impact. Ask what diagnosis and treatment plan fit that pattern, and how progress should be assessed.
Do not stop a prescribed medicine to test whether a forum claim is true. Nor should a return of symptoms automatically lead to another experimental course.
The cited literature does not establish a permanent DSIP sleep reset or a general maintenance schedule. Keeping that limit clear protects the useful part of the research from being expanded into a promise the study did not test.